Sanofi Buys Dynavax for $2.2B, Boosting Hepatitis B & Shingles Vaccines

Sanofis $2.2B acquisition of Dynavax Technologies boosts its Hepatitis B vaccine and shingles market presence, offering a 39% premium over Dynavaxs closing price. The deal, set to close in Q1 2023, provides a lucrative payday for investors and expands Sanofis lifelong disease protection portfolio.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.